HOME >> BIOLOGY >> NEWS
ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 11, 2007). ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a report in the prestigious Nature publication Leukemia confirming the positive clinical activity of the company's lead compound, Ceflatonin against Gleevec-resistant, chronic myeloid leukemia (CML) associated with the T315I Bcr-Abl mutation.

The T315I mutation is known to confer resistance to both Gleevec (imatinib mesylate) and second-generation tyrosine kinase inhibitors (dasatinib and nilotinib). Recent publications indicate that the incidence of T315I-associated resistance is increasing and confirm that this mutation is likely to become the prevalent mutation in those who fail tyrosine kinase inhibitor therapy.

The publication by Dr. Laurence Legros of the Hpital Archet, Nice, France and colleagues describes the treatment with Ceflatonin (homoharringtonine, HHT) of a Gleevec-resistant, chronic-phase CML patient with the T315I Bcr-Abl mutation. The authors report that the patient experienced a 50 percent reduction of T315I Bcr-Abl levels within 2.5 months of treatment initiation, and the complete disappearance of the mutation within 5.5 months of treatment. Complete hematological response (CHR) was achieved after three cycles of therapy.

Based on the clinical results, the authors believe that the rapid and complete disappearance of the T315I mutation might suggest a particular sensitivity of this mutation to HHT. The authors conclude that HHT "may provide an alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking."

The authors also noted some hematologic toxicities (neutropenia, thrombocytopenia and anemia), but confirmed that the toxicity of HHT was "easy to manage".

"We are delighted with this publication that reinforces our belief in the potential of Ceflatonin to treat patient
'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
11-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2019)... ... May 31, 2019 , ... ... & Rosati recently invested in BioFactura’s $6M Series B Financing Round. , ... value-added institutional investors who bring significant financial and business resources to bear as ...
(Date:5/31/2019)... ... May 30, 2019 , ... Join Julie ... live webinar on Wednesday, June 19, 2019 at 1pm EDT where she ... teams, data management teams and contract research organizations (CROs) can improve collaboration, auditing, ...
(Date:5/26/2019)... ... May 24, 2019 , ... Zolgensma (Novartis, AveXis), an ... was approved for clinical use in the United States by the Food and Drug ... therapy approved to treat inherited genetic disorders in the United States and the second-ever ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... ... May 13, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is ... redesigned website aims to improve LDA’s ability to communicate directly with the marketplace; ...
(Date:5/7/2019)... ... May 06, 2019 , ... ... the growing number of repositories being asked to store cellular products being ... team of contributors who are world leaders, who have shared their expertise in ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... REPROCELL USA Inc. has demonstrated its ability to provide various services and ... to enhance customer satisfaction through the effective implementation of its quality management ...
(Date:5/2/2019)... Calif. (PRWEB) , ... May 02, 2019 , ... ... clinical genetics testing company, will present results documenting discrepancies between U.S. insurer policies ... guidelines for patients at risk for hereditary breast and ovarian cancer (HBOC). ...
Breaking Biology Technology:
Cached News: